No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Turn Therapeutics Inc. (TTRX) stock was $11.77 as of Oct 6, 2026, 3:04 PM EDT, down 4.79% from the previous close.
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues.
Biotechnology · Westlake Village, CA
LATEST PRICE
$11.77
52-WEEK RANGE
$2.57 - $26.50
BETA
2.05
% FROM 52W HIGH
-55.59%
MARKET CAP
$350.53M
DIVIDEND YIELD
Never paid
N/A
PE RATIO
trailing TTM
N/A
PE RATIO (FWD)
forward FY estimate
N/A
P/B RATIO
510.32
P/S RATIO
TTM
N/A
P/OCF RATIO
TTM
N/A
EV/EBITDA
TTM
N/A
DEBT / EQUITY
8.91
REVENUE TTM
$0
GROSS MARGIN TTM
0.00%
NET PROFIT MARGIN TTM
0.00%
REVENUE GROWTH TTM
TTM vs prior TTM
N/A
REVENUE CAGR 3Y
N/A
REVENUE CAGR 5Y
N/A
TTM TOTAL RETURN
N/A
3Y TOTAL RETURN
annualized (CAGR)
N/A
5Y TOTAL RETURN
annualized (CAGR)
N/A
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.09
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.20
vs Estimate
$-0.02
Revenue
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$25.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.09 | $-0.09 | $-0.08 | 2 |
| Quarter ending Dec 2026 | $-0.17 | $-0.12 | $-0.07 | 2 |
| Quarter ending Mar 2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Quarter ending Jun 2027 |
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TTRX | $350.53M | $11.77 | -4.79% | N/A | N/A | N/A | N/A |
| 2OBIO | $351.80M | $5.88 | -2.57% | +121.66% | -9.35% | N/A | vs TTRX |
| 3RLMD | $346.66M | $3.31 | -5.03% | +49.71% | -7.68% | +12.41% | vs TTRX |
| 4VMD | $356.54M | $9.36 | +1.31% | +33.15% | +10.93% | N/A | vs TTRX |
| 5OCGN | $356.88M | $1.05 | +1.19% | -41.09% | -31.57% | -40.73% | vs TTRX |
| 6ENTA | $357.11M | $12.28 | -2.53% | +21.86% | -26.94% | -7.11% | vs TTRX |
+112.4% upside
Low
$24.00
Current
$11.77
High
$26.00
| $-0.11 |
| $-0.11 |
| $-0.11 |
| 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.44 | $-0.44 | $-0.44 | 1 |
| FY 2027 | $-0.42 | $-0.42 | $-0.42 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $250000.00 | $250000.00 | $250000.00 | 1 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $300000.00 | $300000.00 | $300000.00 | 2 |
| FY 2027 | $3.37M | $3.37M | $3.37M | 2 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
